Loading organizations...
Key people at CS Capital.
CS Capital was founded in 2010 by Min Lou (CEO & Co-founder).
CS Capital is a prominent private equity firm in China, specializing in growth equity investments. It identifies and supports technically excellent companies exhibiting global innovation across Smart EV, Life Science, and Digitalization sectors. The firm provides financial and strategic guidance, fostering enterprise development for significant expansion and market leadership.
Established in 2010 by co-founder Min Lou, CS Capital's inception was driven by the insight to capitalize on burgeoning growth opportunities within China's strategic, high-potential industries. Founders recognized the critical need for targeted capital and operational expertise to propel domestic innovators onto the global stage.
CS Capital primarily partners with growth-stage companies in its core investment areas, collaborating with management teams to accelerate commercialization and expansion. Its overarching vision is to cultivate an interconnected “ecosphere” uniting government, industry, and finance, elevating portfolio companies into international leaders and shaping future industrial landscapes.
Key people at CS Capital.
CS Capital has 4 tracked investments across 4 companies. The latest tracked deal is $72.5M Series B in Biointron in August 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 31, 2022 | Biointron | $72.5M Series B | — | Gaorong Capital, October Capital |
| Aug 22, 2022 | Porton Advanced Solutions | $80.0M Series B | China Merchants Capital, Merchant Health | Fosun Health Capital, Gortune Investment, HM Capital, Momentum Ventures, Porton Pharma Solutions, Ruilian Xingshan Capital, Sdictk |
| May 19, 2022 | Laekna Therapeutics | $61.0M Series D | CS Capital | Infinity Capital, Worldstar, Yanchuang Capital |
| Nov 20, 2021 | Tavotek Biotherapeutics | $35.0M Series B | CS Capital | Fontus Capital |
CS Capital was founded in 2010 by Min Lou (CEO & Co-founder).
